Solo-1 trial results have shown that Lynparza improved progression-free survival rates in BRCA-mutated ovarian cancer patients, in complete or partial response following first-line standard platinum-based chemotherapy, by 70% versus placebo. For patients being treated with Lynparza, the median progression-free survival rate at 41 months was not reached, and 60.4% of patients remained progression-free at 36 months. For patients being treated with placebo, the median progression-free survival rate was 13.8 months and 26.9% of patients remained progression-free at 36 months.
AZ’s EVP, Global Medicines Development and chief medical officer, Sean Bohen, said: “There is currently a significant unmet need in the treatment of advanced ovarian cancer because 70 percent of women relapse within the first three years after their initial treatment. The remarkable results of the SOLO-1 trial, which showed that 60 percent of women with newly-diagnosed, advanced BRCA-mutated ovarian cancer remained progression-free at three years, highlight the potential of Lynparza as a first-line maintenance therapy in this setting.”
“Positive SOLO-1 trial results for AZ/MSD’s Lynparza“
Co-principal investigator of the SOLO-1 trial, Kathleen Moore, said, “Women with ovarian cancer are often diagnosed with advanced disease, which unfortunately is associated with poor long-term survival rates. The newly-diagnosed setting is our best opportunity to achieve a sustained remission, since once a patient’s ovarian cancer recurs, it is typically incurable. The SOLO-1 results demonstrate the potential of LYNPARZA maintenance therapy earlier in the treatment pathway and reinforce the importance of identifying a patient’s BRCA mutation status at the time of diagnosis – these results could change the way we treat women with advanced BRCA-mutated ovarian cancer.”